Species of the genus Eryngium L. of the Apiaceae family are successfully used in folk medicine in various countries worldwide, but they are hardly implemented in official medicinal and pharmaceutical practices. Therefore, it is advisable to conduct phytochemical and pharmacological research in E. planum L. herb extracts to develop and implement new phytomedicines based on this raw material. Purified water, and 40% and 70% ethanol were used for obtaining soft extracts. A total of seven hydroxycinnamic acids, six flavonoids, and three tannin metabolites were identified and quantified in the E. planum extracts by HPLC. These extracts were characterized as practically non-toxic medicines (V toxicity class, LD50 > 5000 mg/kg). The hepatoprotective activity of the E. planum extracts has been established. They were affected to reduce serum thiobarbituric acid (TBA) levels by 29.3%, 31.5%, and 32.4%, respectively, compared to untreated animals and in liver homogenate by 59.5%, 65.4%, and 66.8%, respectively. The alanine transaminase (ALT) activity decreased by 26.9%, 30.8%, and 33.8%, respectively. The aspartate transaminase (AST) activity decreased by 23.9 %, 25.7 %, and 30.5 %, respectively. The sedative activity of E. planum extracts was studied for the first time. The 70% ethanol extract has the most pronounced sedative effect due to a significant decrease in motor activity (by 2.4 times compared to the control group) in the «Open Field test» and reduction in concern in the «Cube tests», «Raised Cross Maze», and "Black and White Camera". This extract also demonstrates a moderate antibacterial effect against gram-positive microorganisms (8–10 mm), including staphylococci, streptococci, and bacilli. These results provide a foundation for further preclinical and clinical studies of the dry extract of E. planum herb (extractant: 70% ethanol) to integrate it into modern medical practice and develop new supplements.
Read full abstract